<DOC>
	<DOCNO>NCT02399384</DOCNO>
	<brief_summary>The investigator propose correlate 1 ) cardiac MRI pericardial adipose volume , 2 ) presence pericardial monocytes 3 ) circulate immune biomarkers person without CHD HIV infection compare seronegative control know CHD . The investigator aim test hypothesis high amount pericardial fat deposition increase presence monocyte within adipose tissue associate underlying coronary artery disease person HIV infection measure cardiac MRI .</brief_summary>
	<brief_title>Pericardial Fat Inflammation HIV Patients Controls</brief_title>
	<detailed_description>Methods Procedures : Screening Assessments Patients potentially meet inclusion criterion identify Infectious Disease Center and/or cardiac catheterization laboratory coronary angiogram cardiac CT angiogram , without evidence CAD . Their record review inclusion exclusion criterion inform consent obtain prior research related procedure member research team project . A screening visit do obtain informed consent . BUN Creatinine do screening ensure safety MRIprocedure . In HIV-infected subject HIV-1 RNA CD4+ lymphocyte test obtain last 60 day , do screening . Screening visit last approximately 30-60 minute . Entry Visit - MRI The entry visit occur within 14 day screen assessment . All female patient child bear potential negative pregnancy test . If BUN/Creatinine result great 14 day old , repeat STAT prior begin MRI procedure . Whole blood drawn biobanking ( PBMCs , Plasma Serum ) well fast lipid obtain . An IV start MRI laboratory . All participant undergo initial cardiac MRI contrast evaluation cardiac function , chamber size , rest perfusion , pericardial adipose volume/mass , myocardial edema determination infarction . The GE Signa Horizon 1.5T Magnet use obtain image . Sequences obtain include Double IR , Triple IR , T2 Stars , SSFP delay gadolinium enhancement imaging . After initial CMR day 1 , Feraheme 5 mg/kg IV administer . Feraheme ( 30 mg/mL ) available intravenous injection single use vial . Each vial contain 510 mg elemental iron 17 mL . Feraheme administer undiluted intravenous injection deliver rate 1 mL/sec ( 30 mg/sec ) filter needle . Patients monitor 1 hour administration sign allergic reaction . The total amount time Entry visit 4 hour . Day 2 3 - repeat MRI A second , limited cardiac MRI obtain 48-72 hour injection Feraheme determine presence monocyte/macrophages adipose tissue . The GE Signa Horizon 1.5T Magnet use obtain image . Imaging T2 Stars Triple IR sequence . Data To Collected : MRI data collect include : Left ventricular right ventricular ejection fraction Left ventricular wall motion Edema Resting myocardial perfusion Pericardial adipose tissue volume T2 star value pericardial fat pre-Feraheme post-Feraheme Late gadolinium enhancement ( scar assessment distribution ) Valvular assessment Extracardiac assessment - pericardial effusion , pleural effusion , ascites Vital sign ( height , weight , blood pressure , heart rate , BSA ) Additional Data collect available clinical record . Left Heart catheterization Presence absence coronary artery disease . The general anatomy , lesion location severity , presence , location type stent , leave ventricular end diastolic pressure , systemic blood pressure , aortic valve gradient Echocardiogram Ejection fraction Regional wall motion abnormality Inducible ischemia stress echo perform Nuclear Stress study Presence absence ischemia infarction Distribution perfusion abnormality . Ejection fraction TID ( transient ischemic dilatation ) End Diastolic Volume End Systolic Volume Medical History ( Presence Absence ) Sociodemographic information ( age , race/ethnicity , etc ) HIV related medical information Myocardial Infarction Hypercholesterolemia Hypertension Ventricular Tachycardia Stent Placement Bypass Surgery Diabetes Peripheral Vascular Disease Stroke Smoking ( Lifetime Pack-year history Current status ) Family History Heart Disease Medications Current use last 30 day Anti-hypertensive ( Beta Blockers , Calcium Channel Blockers , Ace Inhibitors , Angiotensin Receptor Blockers , Alpha Antagonists ) Current use last 30 day Diuretics Lifetime use Statins Current use last 30 day Insulin anti-diabetic medication Lifetime use Antiretroviral Therapy Laboratory Results HIV-1 Viral Load last year Nadir CD4 Count CD4 count last year ( include percentage ) CD8/CD8 percent last year Troponins ( around time MI applicable ) Most recent Creatinine within 90 day study entry Most recent BUN within 90 day study entry If subject diabetes , hemoglobin A1C Fructosamine level last year . Primary endpoint Pericardial adipose tissue volume Change T2 star value ( assessment iron deposition marker inflammation ) Secondary endpoint Correlation inflammatory biomarkers Pericardial adipose tissue volume change T2 star value Correlation prior HIV relate Coronary Heart Disease risk factor event inflammatory biomarkers , pericardial adipose tissue volume change T2 star value . Data Analysis Data store RedCap data base . Statistical analysis perform use MedCalc . Continuous variable analyze use analysis Variance ( ANOVA ) . Non-continuous variable analyze use chi square test . Data Monitoring This study monitor trained coordinator involve research project enrollment first subject , fifth subject last subject . The monitoring plan include 100 % verification consent process inclusion exclusion criterion . Monitoring appropriate documentation collection study data do first three subject completion last subject study participant . Additional monitoring conduct base risk base assessment monitor . Data Safety Monitoring Board ( DSMB ) No DSMB establish study . The risk MRI phlebotomy low test agent use Food Drug Administration ( FDA ) approve . The investigator monitor closely adverse event unanticipated number severity event occur , Institutional Review Board ( IRB ) notify DSMB convene . Data Storage Confidentiality : Participant medical information store electronically Redcap database . Each subject unique study ID assign data . The name medical record number research participant keep lock key separate actual research data recap . No identify information present research database . Access participant medical information contain within research project restrict involved investigator study personnel . Password protection data file use . Any paper base data pertain individual store locked secure location . De-identified participant medical record information store indefinite period time per institutional policy University Cincinnati ( UC ) . Setting : University Cincinnati Medical Center , affiliate MRI facility Laboratory Methods Facilities : Peripheral blood mononuclear cell , plasma serum obtain stored subsequent measurement ; hsCRP , IL-6 , D-dimer , sCD163 , CXCL10 , flow cytometry measure monocyte activation additional study . DNA isolate may send genetic testing relate inflammation , lipid disorder atherosclerosis . Fasting lipid obtain day cardiac MRI CD4 count HIV RNA quantitation obtain within 60 day cardiac MRI record . Estimated Period Time Complete Study : 12 month , end June 30 , 2015 .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>&gt; 18 year age History HIV disease history HIV Prior history leave heart catheterization CTA indicate presence absence CAD . Unable contrast enhance cardiac MRI , ( i.e . ferromagnetic foreign body , inability follow verbal instruction , prior history allergic reaction gadolinium , history nephrogenic systemic fibrosis , severe renal dysfunction GFR &lt; 30 ml/min/1.73 m2 , severe claustrophobia/anxiety ) ; Chronic kidney disease patient undergo hemodialysis peritoneal dialysis Allergy Iron Compounds ; Pregnant female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cardiac Magnetic Resonance ( CMR )</keyword>
</DOC>